Dyadic Reports First Quarter 2019 Financial Results and Recent Developments
Trading as DYAI on NASDAQ Capital Market as of April 17 New fully-funded proof-of-concept research collaborations with two top twenty-five pharmaceutical companies Sub-licensing agreements with Luina Bio and Alphazyme Collaboration with Serum Institute of India to develop and manufacture up to twelve antibodies and vaccines Execution of multiple strategic research initiatives further reinforces strength of Dyadic's C1 gene expression platform,...
Read more









